(2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide manufacturers
- BL-918
-
- $45.00 / 1mg
-
2026-02-01
- CAS:2101517-69-3
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide Basic information | | Uses |
| Product Name: | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide | | Synonyms: | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide;BL-918
(BL918);BL 918 NEW;inhibit,disease,BL-918,cytoprotective,BL 918,BL918,Autophagy,kinase,autophagic,Unc-51 like kinase,Orally,Parkinson’s,ULK,Inhibitor;Benzeneacetamide, α-[[[[3,5-bis(trifluoromethyl)phenyl]amino]thioxomethyl]amino]-N-(2,4-difluorophenyl)-, (αR)-;BL 918 - Bio-X;BL-918, 10 mM in DMSO;BL-918 ，S0819 | | CAS: | 2101517-69-3 | | MF: | C23H15F8N3OS | | MW: | 533.4369256 | | EINECS: | 825-946-9 | | Product Categories: | | | Mol File: | 2101517-69-3.mol | ![(2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide Structure](CAS/20200331/GIF/2101517-69-3.gif) |
| | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide Chemical Properties |
| density | 1.508±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 250 mg/mL (468.66 mM) | | form | A solid | | pka | 11.13±0.70(Predicted) | | color | White to off-white | | InChIKey | BDBWQANRZRCMMD-DETXXQSHNA-N | | SMILES | C(NC1=CC=C(F)C=C1F)(=O)[C@H](NC(=S)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C1=CC=CC=C1 |&1:11,r| |
| | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide Usage And Synthesis |
| Uses | BL 918 is a potent small-molecule activator of UNC-51-like kinase 1 (ULK1), a serine-threonine kinase involved in autophagy. Promotes cytoprotective autophagy in MPP+-treated SH-SY5Y cells, via the ULK complex. Improves motor dysfunction and reduces loss of dopaminergic neurons, mediated by MPTP, in in vivo models of Parkinson’s disease. | | Uses | BL 918 is a potent small-molecule activator of UNC-51-like kinase 1 (ULK1), a serine-threonine kinase involved in autophagy. Promotes cytoprotective autophagy in MPP+-treated SH-SY5Y cells, via the ULK complex. Improves motor dysfunction and reduces loss of dopaminergic neurons, mediated by MPTP, in in vivo models of Parkinson’s disease. | | in vivo | BL-918 (compound 33i; 20, 40, or 80 mg/kg/day; oral gavage; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP) attenuates the loss of DA and its metabolites. BL-918 obviously decreases the levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA)[1].
| Animal Model: | Male C57BL/6 mice (eight-week old) weighing between 20 and 25 g[1] | | Dosage: | 20, 40, or 80 mg/kg | | Administration: | Oral gavage; daily; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP | | Result: | Attenuated the loss of DA and its metabolites.
|
| | IC 50 | ULK1: 24.14 nM (EC50); ULK1: 0.719 μM (Kd) |
| | (2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide Preparation Products And Raw materials |
|